Several studies indicate that the development of Alzheimer's disease (AD) has strong interactions with immune mechanisms within the brain, indicating a close association between inflammation in the central nervous system and the progression of neurodegeneration. Despite considerable progress in understanding the inflammatory aspects of AD, several of them remain unresolved. Pro-inflammatory cytokines and microglia are pivotal components in the inflammatory cascade. Among these, the role of interleukin-8 (IL-8) in neurodegeneration seems complex and multifaceted, involving inflammation, neurotoxicity, blood-brain barrier disruption, and oxidative stress, and is still poorly characterized. We conducted a review to describe the evidence of IL-8 involvement in AD. IL-8 is a cytokine known for its proinflammatory properties and typically produced by macrophages, predominantly functions as a chemotactic signal for attracting neutrophils to inflamed sites in the bloodstream. Interestingly, IL-8 is also present in the brain, where it is primarily released by microglia in response to inflammatory signals. This review aims to provide a comprehensive overview of the structure, function, and regulatory mechanisms of IL-8 relevant to AD pathology.
BreijyehZKaramanR. Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules2020; 25: 5789.
2.
DeKoskySTMarekK. Looking backward to move forward: early detection of neurodegenerative disorders. Science2003; 302: 830–834.
3.
PlessAWareDSagguS, et al.Understanding neuropsychiatric symptoms in Alzheimer’s disease: challenges and advances in diagnosis and treatment. Front Neurosci2023; 17: 1263771.
4.
ArmstrongRA. Risk factors for Alzheimer’s disease. Folia Neuropathol2019; 57: 87–105.
5.
PlantoneDPardiniMRighiD, et al.The role of TNF-α in Alzheimer’s disease: a narrative review. Cells2024; 13: 54.
6.
CaoJHouJPingJ, et al.Advances in developing novel therapeutic strategies for Alzheimer’s disease. Mol Neurodegener2018; 13: 64.
7.
OzbenTOzbenS. Neuro-inflammation and anti-inflammatory treatment options for Alzheimer’s disease. Clin Biochem2019; 72: 87–89.
8.
RaniVVermaRKumarK, et al.Role of pro-inflammatory cytokines in Alzheimer’s disease and neuroprotective effects of pegylated self-assembled nanoscaffolds. Curr Res Pharmacol Drug Discov2023; 4: 100149.
CoricaFDe FeoMSGoricaJ, et al.PET Imaging of neuro-inflammation with tracers targeting the translocator protein (TSPO), a systematic review: from bench to bedside. Diagnostics2023; 13: 1029.
11.
KreislWCKimM-JCoughlinJM, et al.PET Imaging of neuroinflammation in neurological disorders. Lancet Neurol2020; 19: 940–950.
12.
CacquevelMLebeurrierNCheenneS, et al.Cytokines in neuroinflammation and Alzheimer’s disease. Curr Drug Targets2004; 5: 529–534.
13.
AziziGNavabiSSAl-ShukailiA, et al.The role of inflammatory mediators in the pathogenesis of Alzheimer’s disease. Sultan Qaboos Univ Med J2015; 15: 305–316.
14.
TsaiS-J. Role of interleukin 8 in depression and other psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry2021; 106: 110173.
15.
MukaidaNHaradaAMatsushimaK. A novel leukocyte chemotactic and activating cytokine, interleukin-8 (IL-8). Cancer Treat Res1995; 80: 261–286.
16.
WhiteJRSarauHM. IL-8 receptor antagonist: basic research and clinical utility. In: NeoteKLettsGLMoserB (eds) Chemokine biology — basic research and clinical application. Progress in inflammation research. Basel: Birkhäuser, 2007, pp.89–102.
17.
LicinioJWongM-LGoldPW. Neutrophil-activating peptide-1/interleukin-8 mRNA is localized in rat hypothalamus and hippocampus. Neuroreport1992; 3: 753–756.
18.
EhrlichLCHuSShengWS, et al.Cytokine regulation of human microglial cell IL-8 production. J Immunol1998; 160: 1944–1948.
19.
RemickDG. Interleukin-8. Crit Care Med2005; 33: S466–S467.
20.
GalimbertiDSchoonenboomNScheltensP, et al.Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol2006; 63: 538.
21.
BaggioliniM. Chemotactic and inflammatory cytokines — CXC and CC proteins. Adv Exp Med Biol1993; 351: 1–11.
22.
ChenXHoltzmanDM. Emerging roles of innate and adaptive immunity in Alzheimer’s disease. Immunity2022; 55: 2236–2254.
23.
JorfiMMaaser-HeckerATanziRE. The neuroimmune axis of Alzheimer’s disease. Genome Med2023; 15: 6.
24.
LaiKSPLiuCSRauA, et al.Peripheral inflammatory markers in Alzheimer’s disease: a systematic review and meta-analysis of 175 studies. J Neurol Neurosurg Psychiatry2017; 88: 876–882.
25.
ShenX-NNiuL-DWangY-J, et al.Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. J Neurol Neurosurg Psychiatry2019; 90: 590–598.
26.
WalkerKALe PageLMTerrandoN, et al.The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap. Mol Neurodegener2023; 18: 37.
27.
EnnerfeltHELukensJR. The role of innate immunity in Alzheimer’s disease. Immunol Rev2020; 297: 225–246.
28.
PlantoneDPardiniMLocciS, et al.B Lymphocytes in Alzheimer’s disease—A comprehensive review. J Alzheimers Dis2022; 88: 1241–1262.
29.
WojcieszakJKuczyńskaKZawilskaJB. Role of chemokines in the development and progression of Alzheimer’s disease. J Mol Neurosci2022; 72: 1929–1951.
30.
Al-GhraiybahNFWangJAlkhalifaAE, et al.Glial cell-mediated neuroinflammation in Alzheimer’s disease. Int J Mol Sci2022; 23: 10572.
31.
ThakurSDhapolaRSarmaP, et al.Neuroinflammation in Alzheimer’s disease: current progress in molecular signaling and therapeutics. Inflammation2023; 46: 1–17.
32.
CaoWZhengH. Peripheral immune system in aging and Alzheimer’s disease. Mol Neurodegener2018; 13: 51.
33.
FranceschiCCampisiJ. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci2014; 69: S4–S9.
34.
ChaudharyMRChaudharySSharmaY, et al.Aging, oxidative stress and degenerative diseases: mechanisms, complications and emerging therapeutic strategies. Biogerontology2023; 24: 609–662.
35.
AbbatecolaAMGiulianiABiscettiL, et al.Circulating biomarkers of inflammaging and Alzheimer’s disease to track age-related trajectories of dementia: can we develop a clinically relevant composite combination?Ageing Res Rev2024; 96: 102257.
36.
Dias-CarvalhoASáSICarvalhoF, et al.Inflammation as common link to progressive neurological diseases. Arch Toxicol2024; 98: 95–119.
37.
GritsenkoAGreenJPBroughD, et al.Mechanisms of NLRP3 priming in inflammaging and age-related diseases. Cytokine Growth Factor Rev2020; 55: 15–25.
38.
HanCYangYGuanQ, et al.New mechanism of nerve injury in Alzheimer’s disease: β-amyloid-induced neuronal pyroptosis. J Cell Mol Med2020; 24: 8078–8090.
39.
Van ZellerMDiasDSebastiãoAM, et al.NLRP3 Inflammasome: a starring role in amyloid-β- and tau-driven pathological events in Alzheimer’s disease. J Alzheimers Dis2021; 83: 939–961.
40.
YanSXuanZYangM, et al.CSB6B Prevents β-amyloid-associated neuroinflammation and cognitive impairments via inhibiting NF-κB and NLRP3 in microglia cells. Int Immunopharmacol2020; 81: 106263.
41.
HenekaMTKummerMPStutzA, et al.NLRP3 Is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature2013; 493: 674–678.
42.
DempseyCRubio AraizABrysonKJ, et al.Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice. Brain Behav Immun2017; 61: 306–316.
43.
IsingCVenegasCZhangS, et al.NLRP3 Inflammasome activation drives tau pathology. Nature2019; 575: 669–673.
44.
StancuI-CCremersNVanrusseltH, et al.Aggregated tau activates NLRP3–ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded tau pathology in vivo. Acta Neuropathol2019; 137: 599–617.
45.
DeardorffWJGrossbergGT. Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics. Expert Rev Neurother2017; 17: 17–32.
46.
DominguesCda Cruz e SilvaOABHenriquesAG. Impact of cytokines and chemokines on Alzheimer’s disease neuropathological hallmarks. Curr Alzheimer Res2017; 14: 870–882.
47.
LiPHeYYangQ, et al.NEK7 Inhibition attenuates Aβ-induced cognitive impairment by regulating TLR4/NF-κB and the NLRP3 inflammasome in mice. J Clin Biochem Nutr2023; 73: 22–105.
48.
FialaMZhangLGanX, et al.Amyloid-beta induces chemokine secretion and monocyte migration across a human blood-brain barrier model. Mol Med1998; 4: 480–489.
49.
CalsolaroVEdisonP. Neuroinflammation in Alzheimer’s disease: current evidence and future directions. Alzheimers Dement2016; 12: 719–732.
50.
VacinovaGVejražkovaDRusinaR, et al.Regulated upon activation, normal T cell expressed and secreted (RANTES) levels in the peripheral blood of patients with Alzheimer’s disease. Neural Regen Res2021; 16: 796.
51.
AllenSJCrownSEHandelTM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol2007; 25: 787–820.
52.
BaggioliniM. Chemokines in pathology and medicine. J Intern Med2001; 250: 91–104.
53.
PedersenLHojmanP. Muscle-to-organ cross-talk mediated by myokines. Adipocyte2012; 1: 164–167.
54.
LiraSAZalameaPHeinrichJN, et al.Expression of the chemokine N51/KC in the thymus and epidermis of transgenic mice results in marked infiltration of a single class of inflammatory cells. J Exp Med1994; 180: 2039–2048.
55.
KeaneMPArenbergDALynchJP, et al.The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol1997; 159: 1437–1443.
56.
HébertCABakerJB. Interleukin-8: a review. Cancer Invest1993; 11: 743–750.
57.
BratDJBellailACVan MeirEG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol2005; 7: 122–133.
58.
NasserMWRaghuwanshiSKGrantDJ, et al.Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. J Immunol2009; 183: 3425–3432.
59.
KendrickAAHollidayMJIsernNG, et al.The dynamics of interleukin-8 and its interaction with human CXC receptor I peptide. Protein Sci2014; 23: 464–480.
60.
HorcherMRotAAschauerH, et al.IL-8 derivatives with a reduced potential to form homodimers are fully active in vitro and in vivo. Cytokine1998; 10: 1–12.
61.
HoffmannEDittrich-BreiholzOHoltmannH, et al.Multiple control of interleukin-8 gene expression. J Leukoc Biol2002; 72: 847–855.
62.
BaggioliniMDewaldBMoserB. Interleukin-8 and related chemotactic cytokines–CXC and CC chemokines. Adv Immunol1993; 55: 97–179.
63.
XieK. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev2001; 12: 375–391.
64.
HoltmannHEnningaJKälbleS, et al.The MAPK kinase kinase TAK1 plays a central role in coupling the interleukin-1 receptor to both transcriptional and RNA-targeted mechanisms of gene regulation. J Biol Chem2001; 276: 3508–3516.
65.
BaggioliniMWalzAKunkelSL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest1989; 84: 1045–1049.
QaziBSTangKQaziA. Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis. Int J Inflam2011; 2011: 908468.
68.
BernhardSHugSStratmannAEP, et al.Interleukin 8 elicits rapid physiological changes in neutrophils that are altered by inflammatory conditions. J Innate Immun2021; 13: 225–241.
69.
AlsadanyMAShehataHHMohamadMI, et al.Histone deacetylases enzyme, copper, and IL-8 levels in patients with Alzheimer’s disease. Am J Alzheimers Dis Other Demen2013; 28: 54–61.
70.
BiHZhangYWangS, et al.Interleukin-8 promotes cell migration via CXCR1 and CXCR2 in liver cancer. Oncol Lett2019; 18: 4176–4184.
71.
LeeJHorukRRiceGC, et al.Characterization of two high affinity human interleukin-8 receptors. J Biol Chem1992; 267: 16283–16287.
72.
HolmesWELeeJKuangW-J, et al.Structure and functional expression of a human interleukin-8 receptor. J Immunol2009; 183: 2895–2897.
73.
ParkSHDasBBCasagrandeF, et al.Structure of the chemokine receptor CXCR1 in phospholipid bilayers. Nature2012; 491: 779–783.
74.
NguyenDStangelM. Expression of the chemokine receptors CXCR1 and CXCR2 in rat oligodendroglial cells. Dev Brain Res2001; 128: 77–81.
75.
SubileauEARezaiePDaviesHA, et al.Expression of chemokines and their receptors by human brain endothelium: implications for multiple sclerosis. J Neuropathol Exp Neurol2009; 68: 227–240.
76.
RansohoffRMLiuLCardonaAE. Chemokines and chemokine receptors: multipurpose players in neuroinflammation. Int Rev Neurobiol2007; 82: 187–204.
77.
BourdoulousSBensaidAMartinezD, et al.Infection of bovine brain microvessel endothelial cells with Cowdria ruminantium elicits IL-1 beta, −6, and −8 mRNA production and expression of an unusual MHC class II DQ alpha transcript. J Immunol1995; 154: 4032–4038.
78.
SanoHNakagawaNChibaR, et al.Cross-linking of intercellular adhesion molecule-1 induces interleukin-8 and RANTES production through the activation of MAP kinases in human vascular endothelial cells. Biochem Biophys Res Commun1998; 250: 694–698.
79.
DragoniSHudsonNKennyB-A, et al.Endothelial MAPKs direct ICAM-1 signaling to divergent inflammatory functions. J Immunol2017; 198: 4074–4085.
80.
BussianTJAzizAMeyerCF, et al.Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature2018; 562: 578–582.
81.
ZhuYChaiYLHilalS, et al.Serum IL-8 is a marker of white-matter hyperintensities in patients with Alzheimer’s disease. Alzheimers Dement (Amst)2017; 7: 41–47.
82.
NarasimhaluKLeeJLeongY-L, et al.Inflammatory markers and their association with post stroke cognitive decline. Int J Stroke2015; 10: 513–518.
83.
CorsiMMLicastroFPorcelliniE, et al.Reduced plasma levels of P-selectin and L-selectin in a pilot study from Alzheimer disease: relationship with neuro-degeneration. Biogerontology2011; 12: 451–454.
84.
KimS-MSongJKimS, et al.Identification of peripheral inflammatory markers between normal control and Alzheimer’s disease. BMC Neurol2011; 11: 51.
85.
QuintelaIBarrosFFernandez-PrietoM, et al.Interstitial microdeletions including the chromosome band 4q13.2 and the UBA6 gene as possible causes of intellectual disability and behavior disorder. Am J Med Genet A2015; 167: 3113–3120.
86.
MaldžienėŽVaitėnienėEMAleksiūnienėB, et al.A case report of familial 4q13.3 microdeletion in three individuals with syndromic intellectual disability. BMC Med Genomics2020; 13: 63.
87.
AddisonCLDanielTOBurdickMD, et al.The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol2000; 165: 5269–5277.
88.
QinBLiLWangS, et al.Interleukin-8 gene polymorphism −251T > A contributes to Alzheimer’s disease susceptibility. Medicine2016; 95: e5039.
89.
HeinzmannAAhlertIKurzT, et al.Association study suggests opposite effects of polymorphisms within IL8 on bronchial asthma and respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol2004; 114: 671–676.
90.
TaguchiAOhmiyaNShiraiK, et al.Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. Cancer Epidemiol Biomarkers Prev2005; 14: 2487–2493.
91.
FarkasGHofnerPBalogA, et al.Relevance of transforming growth factor-beta1, interleukin-8, and tumor necrosis factor-alpha polymorphisms in patients with chronic pancreatitis. Eur Cytokine Netw2007; 18: 31–37.
92.
HullJ. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax2000; 55: 1023–1027.
93.
HullJAckermanHIslesK, et al.Unusual haplotypic structure of IL8, a susceptibility locus for a common respiratory virus. Am J Hum Genet2001; 69: 413–419.
94.
LiKLiuSYaoS, et al.Interaction between interleukin-8 and methylenetetrahydrofolate reductase genes modulates Alzheimer’s disease risk. Dement Geriatr Cogn Disord2009; 27: 286–291.
95.
AloisiFCarèABorsellinoG, et al.Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-1 beta and tumor necrosis factor-alpha. J Immunol1992; 149: 2358–2366.
96.
AshutoshKouWCotterR, et al.CXCL8 Protects human neurons from amyloid-β-induced neurotoxicity: relevance to Alzheimer’s disease. Biochem Biophys Res Commun2011; 412: 565–571.
97.
ThirumangalakudiLYinLRaoHV, et al.IL-8 induces expression of matrix metalloproteinases, cell cycle and pro-apoptotic proteins, and cell death in cultured neurons. J Alzheimers Dis2007; 11: 305–311.
98.
WatsonKFanG-H. Macrophage inflammatory protein 2 inhibits β-amyloid peptide (1-42)-mediated hippocampal neuronal apoptosis through activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling pathways. Mol Pharmacol2005; 67: 757–765.
99.
FrøylandEDidenko PedersenEKvisselA-K, et al.Effect of acidosis on IL-8 and MCP-1 during hypoxia and reoxygenation in human NT2-N neurons. Brain Res2006; 1113: 64–73.
100.
FranciosiSChoiHBKimSU, et al.IL-8 enhancement of amyloid-beta (Aβ1-42)-induced expression and production of pro-inflammatory cytokines and COX-2 in cultured human microglia. J Neuroimmunol2005; 159: 66–74.
101.
WalkerD. Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia. Neurobiol Aging2001; 22: 957–966.
102.
LueLRydelRBrighamEF, et al.Inflammatory repertoire of Alzheimer’s disease and nondemented elderly microglia in vitro. Glia2001; 35: 72–79.
103.
GriciucAPatelSFedericoAN, et al.TREM2 Acts downstream of CD33 in modulating microglial pathology in Alzheimer’s disease. Neuron2019; 103: 820–835.e7.
104.
WeiLYangXWangJ, et al.H3k18 lactylation of senescent microglia potentiates brain aging and Alzheimer’s disease through the NFκB signaling pathway. J Neuroinflammation2023; 20: 208.
105.
BoccardiVPoliGCecchettiR, et al.miRNAs and Alzheimer’s disease: exploring the role of inflammation and vitamin E in an old-age population. Nutrients2023; 15: 634.
106.
BakshiPMargenthalerELaporteV, et al.Novel role of CXCR2 in regulation of γ-secretase activity. ACS Chem Biol2008; 3: 777–789.
107.
BakshiPMargenthalerEReedJ, et al.Depletion of CXCR2 inhibits γ-secretase activity and amyloid-β production in a murine model of Alzheimer’s disease. Cytokine2011; 53: 163–169.
108.
FoleyKEWinderZSudduthTL, et al.Alzheimer’s disease and inflammatory biomarkers positively correlate in plasma in the UK-ADRC cohort. Alzheimers Dement2024; 20: 1374–1386.
109.
VazMDominguesCTrindadeD, et al.IL-8 and MCP-1 impact on tau phosphorylation and phosphatase activity. Curr Alzheimer Res2021; 17: 985–1000.
110.
LiuY-JGuoD-WTianL, et al.Peripheral T cells derived from Alzheimer’s disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-α-dependent. Neurobiol Aging2010; 31: 175–188.
111.
RyuJKChoTChoiHB, et al.Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimer’s disease. J Neuroinflammation2015; 12: 144.
112.
ZhangX-FZhaoY-FZhuS-W, et al.CXCL1 Triggers caspase-3 dependent tau cleavage in long-term neuronal cultures and in the hippocampus of aged mice: implications in Alzheimer’s disease. J Alzheimers Dis2015; 48: 89–104.
113.
RamanDMilatovicS-ZMilatovicD, et al.Chemokines, macrophage inflammatory protein-2 and stromal cell-derived factor-1α, suppress amyloid β-induced neurotoxicity. Toxicol Appl Pharmacol2011; 256: 300–313.
114.
ZhangKTianLLiuL, et al.CXCL1 Contributes to β-amyloid-induced transendothelial migration of monocytes in Alzheimer’s disease. PLoS One2013; 8: e72744.
115.
XiaMHymanBT. GROα/KC, a chemokine receptor CXCR2 ligand, can be a potent trigger for neuronal ERK1/2 and PI-3 kinase pathways and for tau hyperphosphorylation—a role in Alzheimer’s disease. J Neuroimmunol2002; 122: 55–64.
116.
SokolovaAHillMDRahimiF, et al.Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer’s disease. Brain Pathol2009; 19: 392–398.
117.
DoroszkiewiczJKulczynska-PrzybikADulewiczM, et al.The cerebrospinal fluid interleukin 8 (IL- 8) concentration in Alzheimer’s disease (AD). Alzheimers Dement2021; 17: e051317.
118.
ZhangJSokalIPeskindER, et al.CSF Multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol2008; 129: 526–529.
119.
AksnesMAassHCDTiimanA, et al.Serum amyloidogenic nanoplaques and cytokines in Alzheimer’s disease: pilot study in a small naturalistic memory clinic cohort. J Alzheimers Dis2022; 86: 1459–1470.
120.
SwardfagerWLanctôtKRothenburgL, et al.A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry2010; 68: 930–941.
121.
ZulianiGGuerraGRanziniM, et al.High interleukin-6 plasma levels are associated with functional impairment in older patients with Vascular dementia. Int J Geriatr Psychiatry2007; 22: 305–311.
122.
HesseRWahlerAGummertP, et al.Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1β. BMC Neurol2016; 16: 185.
123.
CapognaEWatneLOSørensenØ, et al.Associations of neuroinflammatory IL-6 and IL-8 with brain atrophy, memory decline, and core AD biomarkers – in cognitively unimpaired older adults. Brain Behav Immun2023; 113: 56–65.
124.
BrunoMBonomiCGRicciF, et al.Blood–brain barrier permeability is associated with different neuroinflammatory profiles in Alzheimer’s disease. Eur J Neurol2024; 31: 1609.
125.
XiaMQinSMcNamaraM, et al.Interleukin-8 receptor B immunoreactivity in brain and neuritic plaques of Alzheimer’s disease. Am J Pathol1997; 150: 1267–1274.
126.
HorukRMartinAWWangZ, et al.Expression of chemokine receptors by subsets of neurons in the central nervous system. J Immunol1997; 158: 2882–2890.
127.
GertjeECJanelidzeSvan WestenD, et al.Associations between CSF markers of inflammation, white matter lesions, and cognitive decline in individuals without dementia. Neurology2023; 100: 1812–1824.
128.
AraújoDCVelosoAAGomesKB, et al.A novel panel of plasma proteins predicts progression in prodromal Alzheimer’s disease. J Alzheimers Dis2022; 88: 549–561.
129.
AriesMLHensley-McBainT. Neutrophils as a potential therapeutic target in Alzheimer’s disease. Front Immunol2023; 14: 1123149.
130.
BoylesJSBeidlerCBStriflerBA, et al.Discovery and characterization of a neutralizing pan-ELR+CXC chemokine monoclonal antibody. MAbs2020; 12: 1831880.
131.
TranTTNTranQHNguyenQT, et al.LY3041658/ interleukin-8 complex structure as targets for IL-8 small molecule inhibitors discovery using a combination of in silico methods. SAR QSAR Environ Res2022; 33: 753–778.
